7 Hills Logo.png
7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors
03 sept. 2024 14h02 HE | 7 Hills Pharma
7 Hills safely doses first cancer patient with alintegimod, a novel selective integrin activator designed to improve the efficacy of checkpoint blockade.
22157.jpg
Nivolumab Market Forecasts Indicate Robust Growth Driven by Advances in Cancer Immunotherapy and Increased Global Access to Care
15 févr. 2024 14h57 HE | Research and Markets
Dublin, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The "Nivolumab Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Recent advancements in cancer treatment and the...
Adagene_Logo_GNW.png
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
16 janv. 2024 17h01 HE | Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
22157.jpg
Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032
14 déc. 2023 10h08 HE | Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
Adagene_Logo_GNW.png
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
31 août 2023 07h32 HE | Adagene Inc.
- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy – -...
7 Hills Logo.png
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
22 mai 2023 13h05 HE | 7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
Adagene_Logo_GNW.png
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
28 mars 2023 16h30 HE | Adagene Inc.
- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with...
22157.jpg
Global Squamous Non-Small Cell Lung Cancer Market Report 2021-2031: Marketed, Clinical and Preclinical Molecules Available/Being Developed
22 oct. 2021 04h58 HE | Research and Markets
Dublin, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The "Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report has been added to...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
18 mars 2021 16h15 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
15 déc. 2020 08h05 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...